Related Experiment Video

Updated: Aug 10, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

Ebola and Marburg viruses: pathogenesis and development of countermeasures

Lisa E Hensley1, Steven M Jones, Heinz Feldmann

  • 1Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA.

Current Molecular Medicine
|December 27, 2005
PubMed

Insights

Ebola and Marburg viruses cause severe hemorrhagic fevers with high fatality rates. Research is advancing to understand filoviral pathogenesis and develop new therapies and vaccines.

Area of Science:

  • Virology
  • Pathogen Research
  • Public Health

Background:

  • Ebola and Marburg viruses (Filoviridae family) are known emerging pathogens causing severe hemorrhagic fevers.
  • Outbreaks are geographically restricted but associated with high case fatality rates (>80%) in humans and impacts on wild ape populations.
  • Current therapeutic and vaccine options for human use are limited.

Purpose of the Study:

  • To review the progress in understanding filoviral pathogenesis.
  • To highlight the development of new tools for studying viral life cycles.
  • To identify potential therapeutic targets and advancements in vaccine development.

Main Methods:

  • Review of current scientific literature on filoviral pathogenesis.
  • Discussion of advancements in molecular biology tools for virological research.
  • Analysis of progress in vaccine development strategies.

Main Results:

  • Understanding of molecular mechanisms of filoviral pathogenesis is increasing.
  • New tools facilitate the elucidation of critical regulatory elements in the viral life cycle.
  • Substantial progress has been made in developing recombinant vaccines.

Conclusions:

  • Increased understanding of filoviral pathogenesis provides new targets for therapeutic interventions.
  • Development of novel vaccines against Ebola and Marburg viruses is progressing.
  • Continued research is crucial for combating these deadly emerging pathogens.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Procedures for the Identification of SARS-CoV-2 Entry Inhibitors as Potential Antivirals using MLV-Based Pseudoviruses11:43

Procedures for the Identification of SARS-CoV-2 Entry Inhibitors as Potential Antivirals using MLV-Based Pseudoviruses

Published on: February 27, 2026

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...